Explore
Validate
Learn45-1589-42
antibody from Invitrogen Antibodies
Targeting: KIR2DL1
47.11, CD158A, cl-42, nkat1, p58.1
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 45-1589-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD158a/h/g Monoclonal Antibody (HP-MA4), PerCP-Cyanine5.5, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody HP-MA4 recognizes several CD158 proteins, also known as KIR2D, specifically KIR2DL1 (CD158a), KIR2DS1 (CD158h), KIR2DS3, and KIR2DS5 (CD158g). It does not recognize KIR2DL2 (CD158b1), KIR2DS2 (CD158j), KIR2DL4 (CD158d) or KIR2DS4 (CD158i) and crossreactivity to KIR2DL3 (CD158b2) and KIR2DL5 (CD158f) are unknown. CD158 proteins are members of the killer cell immunoglobulin-like receptors (KIR) family of transmembrane glycoproteins that are expressed on NK cells and a subset of T cells. Each KIR has an isoform with either a short (S) or long (L) cytoplasmic domain which transduces either an activating or inhibitory signal, respectively. The crossreactivity of the HP-MA4 antibody to KIR2DS3 and KIR2DS5 was published in 2013.
- Antibody clone number
- HP-MA4
- Concentration
- 5 µL/Test
Submitted references A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells.
A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.
Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.
Davis ZB, Cogswell A, Scott H, Mertsching A, Boucau J, Wambua D, Le Gall S, Planelles V, Campbell KS, Barker E
PLoS pathogens 2016 Feb;12(2):e1005421
PLoS pathogens 2016 Feb;12(2):e1005421
A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.
Czaja K, Borer AS, Schmied L, Terszowski G, Stern M, Gonzalez A
Genes and immunity 2014 Jan;15(1):33-7
Genes and immunity 2014 Jan;15(1):33-7
Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.
Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2014 Aug;20(8):1252-7
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2014 Aug;20(8):1252-7
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD56 (NCAM) APC (Product # 17-0567-42) and Mouse IgG2b K Isotype Control PerCP-Cyanine5-5 (Product # 45-4732-82) (left) or Anti-Human CD158a/h/g PerCP-Cyanine5-5 (right). Cells in the lymphocyte gate were used for analysis.
